Immunocore has named David Berman as its head of research and development. Berman spent the past decade overseeing the rise of immuno-oncology drugs at AstraZeneca and Bristol-Myers Squibb. At Immunocore, Berman will work to move lead candidate IMCgp100 toward commercialization and advance earlier-stage assets as part of a new-look management team. Source: Fierce Biotech 15/01/2019